WuXi PharmaTech and Open Monoclonal Technology of California reached an agreement that allows WuXi to use OMT's OmniRat, a transgenic rat, to develop therapeutic antibody candidates for WuXi's clients. According to the two companies, OmniRat generates fully human antibodies with great specificity, affinity and manufacturability. It eliminates time-consuming humanization of traditional mouse-derived antibodies and the need for optimization of lead candidates using phage display technology. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});